There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Peggy Wallace Biography and Net Worth

Director of Cognition Therapeutics

Ms. Wallace joined the Cognition Therapeutics board in January 2017. She is a managing partner at Golden Seeds, a venture capital firm dedicated to raising capital for women entrepreneurs and to encouraging both women and men to become active venture investors. She is a general partner of Golden Seeds Fund and Golden Seeds Fund 2 and works with companies and their board representatives to build a post-investment environment that fosters the growth of companies in the portfolio. Ms. Wallace has more than 25 years’ experience on Wall Street at JP Morgan and other organizations, focusing on complex financial structures, credit, derivatives, mergers and acquisitions, and risk management. She holds a B.A. from The George Washington University.

What is Peggy Wallace's net worth?: The estimated net worth of Peggy Wallace is at least $17,507.61 as of November 15th, 2022. Ms. Wallace owns 37,961 shares of Cognition Therapeutics stock worth more than $17,508 as of November 17th. This net worth evaluation does not reflect any other investments that Ms. Wallace may own. Learn More about Peggy Wallace's net worth.
How do I contact Peggy Wallace?: The corporate mailing address for Ms. Wallace and other Cognition Therapeutics executives is , , . Cognition Therapeutics can also be reached via phone at 412-481-2210 and via email at [email protected]. Learn More on Peggy Wallace's contact information.
Has Peggy Wallace been buying or selling shares of Cognition Therapeutics?: Peggy Wallace has not been actively trading shares of Cognition Therapeutics over the course of the past ninety days. Most recently, on Tuesday, November 15th, Peggy Wallace bought 12,500 shares of Cognition Therapeutics stock. The stock was acquired at an average cost of $1.20 per share, with a total value of $15,000.00. Following the completion of the transaction, the director now directly owns 37,961 shares of the company's stock, valued at $45,553.20. Learn More on Peggy Wallace's trading history.
Are insiders buying or selling shares of Cognition Therapeutics?: During the last year, Cognition Therapeutics insiders bought shares 1 times. They purchased a total of 5,700 shares worth more than $9,975.00. The most recent insider tranaction occured on March, 14th when CEO Lisa Ricciardi bought 5,700 shares worth more than $9,975.00. Insiders at Cognition Therapeutics own 20.8% of the company. Learn More about insider trades at Cognition Therapeutics.
Information on this page was last updated on 3/14/2024.

Peggy Wallace Insider Trading History at Cognition Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/15/2022	Buy	12,500	$1.20	$15,000.00	37,961
10/13/2021	Buy	3,000	$12.00	$36,000.00

Peggy Wallace Buying and Selling Activity at Cognition Therapeutics

Cognition Therapeutics Company Overview

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Today's Range

Now: $0.46

$0.46

$0.51

50 Day Range

MA: $0.50

$0.40

$0.61

2 Week Range

Now: $0.46

$0.34

$2.95

Volume

336,050 shs

Average Volume

654,864 shs

Market Capitalization

$19.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34